RecruitingNot ApplicableNCT06626438

Treatable Traits in Interstitial Lung Disease

Sponsor

The University of Western Australia

Enrollment

110 participants

Start Date

Sep 3, 2025

Study Type

INTERVENTIONAL

Conditions

Interstitial Lung Diseases (ILD)

Summary

The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease. The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes). Researchers will compare the treatable traits model to standard of care. Participants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Included participants will be aged ≥ 18 years with a physician-confirmed diagnosis of fibrotic ILD. Fibrotic ILD is defined as presence of fibrotic changes on CT in the opinion of the investigator. All ILD subtypes, excluding sarcoidosis, will be included. Participants will need to be able to provide consent to participate and be established on stable ILD treatment for 1 month prior to study initiation.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.